Mechanisms underlying gastric antiulcerative activity of nitroxides in rats.
Reactive oxygen-derived species and redox-active metals are implicated in mediation of the pathogenesis of gastric mucosal damage and ulceration. Therefore, common strategies of intervention employ metal chelators, antioxidative enzymes, and low-molecular-weight antioxidants (LMWA). The aim of the present study was to elaborate the mechanism(s) responsible for the protection provided by nitroxide radicals in the experimental model of gastric ulceration. Fasted male rats were treated ig with 1 ml 96% ethanol, with or without ig pretreatment with nitroxide or hydroxylamine. In several experiments, rats were injected ip or iv with iron(III) or iron(II) prior to ethanol administration. Rats were sacrificed 10 min after ethanol administration, the stomach was removed, washed and lesion area measured. Pretreatment with iron(III) complexed to nitrilotriacetate or citrate, aggravated the extent of the gastric injury. Conversely, iron(II) inhibited the formation of lesions. The nitroxides were rapidly reduced to their respective hydroxylamines and demonstrated antiulcerative activity for rats treated with iron. However, injecting the hydroxylamine resulted in a similar tissue distribution of nitroxide/hydroxylamnine but did not provide protection. The results show that: (a) the nitroxide radicals, rather than their respective non-radical reduced form, are the active species responsible for protection; (b) nitroxides protect by dismutating O2*- and possibly indirectly increasing the NO level; (c) unlike classical LMWA which are reducing agents, nitroxides inhibit gastric damage by acting as mild oxidants, oxidizing reduced metals and pre-empting the Fenton reaction; and (d) the nitroxides act catalytically as recycling antioxidants.
Samuni
A
A
Department of Molecular Biology, Hadassah Medical School, Hebrew University, Ein Kerem, Jerusalem, Israel. samuni@cc.huji.ac.il
Karmeli
F
F
Moshen
M
M
Rachmilewitz
D
D
D000818:Animals; D000897:Anti-Ulcer Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D003300:Copper / Q000494:pharmacology; D003497:Cyclic N-Oxides / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D006898:Hydroxylamines / Q000378:metabolism / Q000494:pharmacology; D058085:Iron Compounds / Q000494:pharmacology; D008297:Male; D009589:Nitrogen Oxides / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D016877:Oxidants / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013113:Spin Labels; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy*
C110289:4-hydroxy-2,2,6,6--tetramethylpiperidine-1-N-hydroxyl; D000897:Anti-Ulcer Agents; D000975:Antioxidants; D003497:Cyclic N-Oxides; D006898:Hydroxylamines; D058085:Iron Compounds; D009589:Nitrogen Oxides; D016877:Oxidants; D010880:Piperidines; D013113:Spin Labels; D000431:Ethanol; D003300:Copper; C039900:nitroxyl; C001803:tempol